Preminger G M, Knupp C L, Hindsley J P, Jenkins J M, Fried F A, Blatt P M
J Urol. 1984 Jun;131(6):1182-4. doi: 10.1016/s0022-5347(17)50864-2.
Anti-factor VIII antibodies, inherited or acquired inhibitors of the factor VIII molecule, have not been reported previously in the urological literature. Although more common in hemophiliac patients who have received multiple transfusions, this anticoagulant may be the cause of severe hemorrhage in nonhemophiliac patients. We describe a patient with carcinoma of the prostate and an unsuspected anti-factor VIII antibody, who experienced excessive postoperative bleeding and prolonged hospitalization following a vesicolithotomy and bilateral orchiectomy. A prolonged partial thromboplastin time and a significant decrease in measurable factor VIII clotting activity in a patient with no history of bleeding problems are essential clues in making the diagnosis of a factor VIII inhibitor. This coagulation defect is treated best with prothrombin complex concentrates, which contain vitamin K dependent clotting factors.
抗凝血因子VIII抗体,即因子VIII分子的遗传性或获得性抑制剂,在泌尿外科文献中此前未见报道。尽管在接受多次输血的血友病患者中更为常见,但这种抗凝剂可能是非血友病患者严重出血的原因。我们描述了一名前列腺癌患者,其体内存在未被怀疑的抗凝血因子VIII抗体,该患者在膀胱结石切除术和双侧睾丸切除术后出现了术后过度出血和住院时间延长的情况。对于无出血问题病史的患者,活化部分凝血活酶时间延长以及可测量的因子VIII凝血活性显著降低是诊断因子VIII抑制剂的关键线索。这种凝血缺陷用含有维生素K依赖性凝血因子的凝血酶原复合物浓缩剂治疗效果最佳。